Literature DB >> 11669592

Validation of a modified GTNM classification in peri-junctional oesophago-gastric carcinoma and its use as a prognostic indicator.

G H Dickson1, K K Singh, X Escofet, K Kelley.   

Abstract

AIM: A modified GTNM classification (with additional T and N subdivisions) has been used for many years. The aim of this paper was to validate this classification in a group of patients with oesophago-gastric carcinoma and to see if the more detailed information may be useful.
METHOD: The 3-year survival of 139 consecutive patients who survived resection has been related to the individual values of the modified and international classifications.
RESULTS: A step-wise reduction in the survival was found with increasing values of G, T, N and M. The international T3 value yielded a 17.7% survival rate, when subdivided, rates of 37.5%, 17.3% and 3.2% were found. The international N1 value yielded a rate of 12.9% which subdivided into rates of 25.0%, 18.7% and 7.5%.
CONCLUSION: If these results are repeated in a larger and more detailed study, this modified classification may provide added information when discussing prognosis and management. Copyright 2001 Harcourt Publishers Limited.

Entities:  

Mesh:

Year:  2001        PMID: 11669592     DOI: 10.1053/ejso.2001.1200

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  A novel approach to cancer staging: application to esophageal cancer.

Authors:  Hemant Ishwaran; Eugene H Blackstone; Carolyn Apperson-Hansen; Thomas W Rice
Journal:  Biostatistics       Date:  2009-06-05       Impact factor: 5.899

2.  Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.

Authors:  Jia Wang; Nan Wu; Qing-Feng Zheng; Shi Yan; Chao Lv; Shao-Lei Li; Yue Yang
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).

Authors:  Stephen G Swisher; Wayne Hofstetter; Tsung T Wu; Arlene M Correa; Jaffer A Ajani; Ritsuko R Komaki; Lucian Chirieac; Kelly K Hunt; Zhongxing Liao; Alexandria Phan; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

Review 4.  [Grading of tumors in the tubular digestive tract : Esophagus, stomach, colon and rectum].

Authors:  H Bläker
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

5.  Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer.

Authors:  Johannes B Roedl; Dushyant V Sahani; Rivka R Colen; Alan J Fischman; Peter R Mueller; Michael A Blake
Journal:  Eur Radiol       Date:  2008-07-24       Impact factor: 5.315

6.  Patterns of distant organ metastases in esophageal cancer: a population-based study.

Authors:  Dashan Ai; Hanting Zhu; Wenjia Ren; Yun Chen; Qi Liu; Jiaying Deng; Jinjun Ye; Jianhong Fan; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.

Authors:  Yen-Hao Chen; Hung-I Lu; Yu-Ming Wang; Chien-Ming Lo; Shang-Yu Chou; Cheng-Hua Huang; Li-Hsueh Shih; Su-Wei Chen; Shau-Hsuan Li
Journal:  Oncotarget       Date:  2017-10-16

8.  Lung Metastases in Newly Diagnosed Esophageal Cancer: A Population-Based Study.

Authors:  Jida Guo; Shengqiang Zhang; Huawei Li; Mohamed Osman Omar Hassan; Tong Lu; Jiaying Zhao; Linyou Zhang
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

9.  A nomogram for prediction of stage III/IV gastric cancer outcome after surgery: A multicenter population-based study.

Authors:  Zhiying Gao; Jing Ni; Hui Ding; Caiwang Yan; Chuanli Ren; Gang Li; Feng Pan; Guangfu Jin
Journal:  Cancer Med       Date:  2020-06-15       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.